• / Free eNewsletters & Magazine
  • / My Account
Home>China’s Bitter Medicine for Foreign Drug Companies

China’s Bitter Medicine for Foreign Drug Companies

Morningstar Articles

Tue, 1 Oct 2013

BankAtlantic and Ryan Beck struggle through tough times.

Related Videos

  1. Has China Hit Its Growth Limit?

    China's historical growth drivers have started to plateau, but many untapped industries--particularly in the services sector--are set to take the lead, says Seafarer's Andrew Foster.

  2. Reasons to Increase Your Stake in China

    BaoCap's Kevin Carter says there's no imminent landing--hard or soft--in China , and with the country's 35% contribution to global GDP growth, investors should up Chinese exposure in the consumer and tech sectors.

  3. Why China Matters to the World Economy, and Why It Doesn't

    A slowing China will have a profound impact, but it isn't the be-all and end-all to the health of the global economy, says Morningstar's Bob Johnson.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.